23 results on '"Pavasovic V"'
Search Results
2. 085 - FULMINANT, EBV DRIVEN PLASMACYTIC POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) WITH LOSS OF 1P AND GAIN OF TP53/CEP17 AND IGH BONE MARROW INVOLVEMENT AFTER LIVER TRANSPLANT IN 17-MONTH OLD BOY
- Author
-
Pavasovic, V., Cheng, D., Silva, J., and Bartram, J.
- Published
- 2022
- Full Text
- View/download PDF
3. PS948 EXCELLENT RESPONSE TO BLINATUMOMAB IN REFRACTORY B LINEAGE ACUTE LYMPHOBLASTIC LEUKAEMIA IN CHILDREN AND YOUNG ADULTS AFTER DEBULKING CHEMOTHERAPY TO ACHIEVE PARTIAL REMISSION
- Author
-
Clesham, K., primary, Rao, V., additional, Bartram, J., additional, Ancliff, P., additional, Ghorashian, S., additional, O’Connor, D., additional, Pavasovic, V., additional, Rao, A., additional, Samarasinghe, S., additional, Cummins, M., additional, Marks, D., additional, Taylor, G., additional, Nicholson, E., additional, Macartney, C., additional, Patrick, K., additional, Bonney, D., additional, Gibson, B., additional, and Vora, A., additional
- Published
- 2019
- Full Text
- View/download PDF
4. 144 Granulomatous lymphocytic interstitial lung disease (GLILD) in children
- Author
-
Nademi, Z, primary, Davies, G, additional, Devlin, L, additional, Chavasse, R, additional, Maimaris, J, additional, Gilmour, K, additional, Wallis, C, additional, Pavasovic, V, additional, and Worth, A, additional
- Published
- 2018
- Full Text
- View/download PDF
5. LABORATORY SCALE REACTOR FUEL REPROCESSING.
- Author
-
Pavasovic, V
- Published
- 1968
6. Benefits for children with suspected cancer from routine whole-genome sequencing.
- Author
-
Hodder A, Leiter SM, Kennedy J, Addy D, Ahmed M, Ajithkumar T, Allinson K, Ancliff P, Bailey S, Barnard G, Burke GAA, Burns C, Cano-Flanagan J, Chalker J, Coleman N, Cheng D, Clinch Y, Dryden C, Ghorashian S, Griffin B, Horan G, Hubank M, May P, McDerra J, Nagrecha R, Nicholson J, O'Connor D, Pavasovic V, Quaegebeur A, Rao A, Roberts T, Samarasinghe S, Stasevich I, Tadross JA, Trayers C, Trotman J, Vora A, Watkins J, Chitty LS, Bowdin S, Armstrong R, Murray MJ, Hook CE, Tarpey P, Vedi A, Bartram J, and Behjati S
- Subjects
- Humans, Child, Male, Child, Preschool, Female, Adolescent, Infant, Genetic Testing methods, Genome, Human genetics, Genomics methods, Infant, Newborn, Neoplasms genetics, Neoplasms therapy, Neoplasms diagnosis, Whole Genome Sequencing
- Abstract
Clinical whole-genome sequencing (WGS) has been shown to deliver potential benefits to children with cancer and to alter treatment in high-risk patient groups. It remains unknown whether offering WGS to every child with suspected cancer can change patient management. We collected WGS variant calls and clinical and diagnostic information from 281 children (282 tumors) across two English units (n = 152 from a hematology center, n = 130 from a solid tumor center) where WGS had become a routine test. Our key finding was that variants uniquely attributable to WGS changed the management in ~7% (20 out of 282) of cases while providing additional disease-relevant findings, beyond standard-of-care molecular tests, in 108 instances for 83 (29%) cases. Furthermore, WGS faithfully reproduced every standard-of-care molecular test (n = 738) and revealed several previously unknown genomic features of childhood tumors. We show that WGS can be delivered as part of routine clinical care to children with suspected cancer and can change clinical management by delivering unexpected genomic insights. Our experience portrays WGS as a clinically impactful assay for routine practice, providing opportunities for assay consolidation and for delivery of molecularly informed patient care., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
7. Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy.
- Author
-
Gabelli M, Oporto-Espuelas M, Burridge S, Chu J, Farish S, Hedges E, Ware K, Williams L, Young L, Alajangi R, Ancliff P, Bartram J, Bonney D, Chenchara L, Chiesa R, Cugno C, Hodby K, Jalowiec KA, Lazareva A, Lucchini G, Mirci-Danicar OC, Mullanfiroze K, Pavasovic V, Rao A, Rao K, Riley L, Samarasinghe S, Shenton G, Silva J, Vora A, Hough R, Amrolia PJ, and Ghorashian S
- Subjects
- T-Lymphocytes, Antigens, CD19 immunology, Receptors, Chimeric Antigen immunology, Immunotherapy, Adoptive adverse effects, Receptors, Antigen, T-Cell, B-Lymphocytes immunology, B-Lymphocytes metabolism
- Published
- 2024
- Full Text
- View/download PDF
8. Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme.
- Author
-
Oporto Espuelas M, Burridge S, Kirkwood AA, Bonney D, Watts K, Shenton G, Jalowiec KA, O'Reilly MA, Roddie C, Castleton A, Clesham K, Nicholson E, Alajangi R, Prabhu S, George L, Uttenthal B, Gabelli M, Neill L, Besley C, Chaganti S, Wynn RF, Bartram J, Chiesa R, Lucchini G, Pavasovic V, Rao A, Rao K, Silva J, Samarasinghe S, Vora A, Clark P, Cummins M, Marks DI, Amrolia P, Hough R, and Ghorashian S
- Subjects
- Child, Humans, Adolescent, Intention to Treat Analysis, Retrospective Studies, Receptors, Antigen, T-Cell, Immunotherapy, Adoptive adverse effects, Antigens, CD19, Receptors, Chimeric Antigen, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy
- Abstract
CAR T-cell therapy has transformed relapsed/refractory (r/r) B-cell precursor acute lymphoblastic leukaemia (B-ALL) management and outcomes, but following CAR T infusion, interventions are often needed. In a UK multicentre study, we retrospectively evaluated tisagenlecleucel outcomes in all eligible patients, analysing overall survival (OS) and event-free survival (EFS) with standard and stringent definitions, the latter including measurable residual disease (MRD) emergence and further anti-leukaemic therapy. Both intention-to-treat and infused cohorts were considered. We collected data on feasibility of delivery, manufacture, toxicity, cause of therapy failure and followed patients until death from any cause. Of 142 eligible patients, 125 received tisagenlecleucel, 115/125 (92%) achieved complete remission (CR/CRi). Severe cytokine release syndrome and neurotoxicity occurred in 16/123 (13%) and 10/123 (8.1%), procedural mortality was 3/126 (2.4%). The 2-year intent to treat OS and EFS were 65.2% (95%CI 57.2-74.2%) and 46.5% (95%CI 37.6-57.6%), 2-year intent to treat stringent EFS was 35.6% (95%CI 28.1-44.9%). Median OS was not reached. Sixty-two responding patients experienced CAR T failure by the stringent event definition. Post failure, 1-year OS and standard EFS were 61.2% (95%CI 49.3-75.8) and 55.3% (95%CI 43.6-70.2). Investigation of CAR T-cell therapy for B-ALL delivered on a country-wide basis, including following patients beyond therapy failure, provides clinicians with robust outcome measures. Previously, outcomes post CAR T-cell therapy failure were under-reported. Our data show that patients can be successfully salvaged in this context with good short-term survival., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
9. Late Adverse Effects after Treatment for Childhood Acute Leukemia.
- Author
-
Roganovic J, Haupt R, Bárdi E, Hjorth L, Michel G, Pavasovic V, Scheinemann K, van der Pal HJ, Zadravec Zaletel L, Amariutei AE, and Skinner R
- Subjects
- Humans, Child, Hematopoietic Stem Cell Transplantation adverse effects, Long Term Adverse Effects chemically induced, Antineoplastic Agents adverse effects, Leukemia, Myeloid, Acute therapy, Leukemia, Myeloid, Acute drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Cancer Survivors
- Abstract
The aim of this review is to raise awareness and knowledge among healthcare professionals and policymakers about late adverse effects in survivors of childhood leukemia. With contemporary treatment, over 90% of children with acute lymphoblastic leukemia (ALL) and over 60% with acute myeloid leukemia (AML) are cured. Large cohort studies demonstrate that 20% of ALL and most AML survivors have at least one chronic health condition by 20-25 years after diagnosis. These are life-changing or threatening in some survivors and contribute to increased premature mortality. We describe the frequency, causes, clinical features, and natural history of the most frequent and severe late adverse effects in childhood leukemia survivors, including subsequent malignant neoplasms, metabolic toxicity, gonadotoxicity and impaired fertility, endocrinopathy and growth disturbances, bone toxicity, central and peripheral neurotoxicity, cardiotoxicity, psychosocial late effects, accelerated ageing and late mortality. The wide range of late effects in survivors of haemopoietic stem cell transplant is highlighted. Recent developments informing the approach to long-term survivorship care are discussed, including electronic personalized patient-specific treatment summaries and care plans such as the Survivor Passport (SurPass), surveillance guidelines and models of care. The importance of ongoing vigilance is stressed given the increasing use of novel targeted drugs with limited experience of long-term outcomes. CONCLUSION: It is vital to raise awareness of the existence and severity of late effects of childhood leukemia therapy among parents, patients, health professionals, and policymakers. Structured long-term surveillance recommendations are necessary to standardize follow-up care., (Copyright © 2024 Roganovic et al. This article is available under a Creative Commons License (Attribution 4.0 International).)
- Published
- 2024
- Full Text
- View/download PDF
10. CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL.
- Author
-
Ghorashian S, Lucchini G, Richardson R, Nguyen K, Terris C, Guvenel A, Oporto-Espuelas M, Yeung J, Pinner D, Chu J, Williams L, Ko KY, Walding C, Watts K, Inglott S, Thomas R, Connor C, Adams S, Gravett E, Gilmour K, Lal A, Kunaseelan S, Popova B, Lopes A, Ngai Y, Hackshaw A, Kokalaki E, Carulla MB, Mullanfiroze K, Lazareva A, Pavasovic V, Rao A, Bartram J, Vora A, Chiesa R, Silva J, Rao K, Bonney D, Wynn R, Pule M, Hough R, and Amrolia PJ
- Subjects
- Humans, Child, Immunotherapy, Adoptive, Recurrence, Antigens, CD19, T-Lymphocytes, Sialic Acid Binding Ig-like Lectin 2, Receptors, Chimeric Antigen genetics, Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Abstract
Abstract: CD19-negative relapse is a leading cause of treatment failure after chimeric antigen receptor (CAR) T-cell therapy for acute lymphoblastic leukemia. We investigated a CAR T-cell product targeting CD19 and CD22 generated by lentiviral cotransduction with vectors encoding our previously described fast-off rate CD19 CAR (AUTO1) combined with a novel CD22 CAR capable of effective signaling at low antigen density. Twelve patients with advanced B-cell acute lymphoblastic leukemia were treated (CARPALL [Immunotherapy with CD19/22 CAR Redirected T Cells for High Risk/Relapsed Paediatric CD19+ and/or CD22+ Acute Lymphoblastic Leukaemia] study, NCT02443831), a third of whom had failed prior licensed CAR therapy. Toxicity was similar to that of AUTO1 alone, with no cases of severe cytokine release syndrome. Of 12 patients, 10 (83%) achieved a measurable residual disease (MRD)-negative complete remission at 2 months after infusion. Of 10 responding patients, 5 had emergence of MRD (n = 2) or relapse (n = 3) with CD19- and CD22-expressing disease associated with loss of CAR T-cell persistence. With a median follow-up of 8.7 months, there were no cases of relapse due to antigen-negative escape. Overall survival was 75% (95% confidence interval [CI], 41%-91%) at 6 and 12 months. The 6- and 12-month event-free survival rates were 75% (95% CI, 41%-91%) and 60% (95% CI, 23%-84%), respectively. These data suggest dual targeting with cotransduction may prevent antigen-negative relapse after CAR T-cell therapy., (© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.)
- Published
- 2024
- Full Text
- View/download PDF
11. Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group.
- Author
-
Ehrhardt MJ, Leerink JM, Mulder RL, Mavinkurve-Groothuis A, Kok W, Nohria A, Nathan PC, Merkx R, de Baat E, Asogwa OA, Skinner R, Wallace H, Lieke Feijen EAM, de Ville de Goyet M, Prasad M, Bárdi E, Pavasovic V, van der Pal H, Fresneau B, Demoor-Goldschmidt C, Hennewig U, Steinberger J, Plummer C, Chen MH, Teske AJ, Haddy N, van Dalen EC, Constine LS, Chow EJ, Levitt G, Hudson MM, Kremer LCM, and Armenian SH
- Subjects
- Child, Humans, Adolescent, Young Adult, Survivors, Antibiotics, Antineoplastic adverse effects, Mitoxantrone, Neoplasms drug therapy, Neoplasms radiotherapy, Cardiomyopathies chemically induced, Cardiomyopathies diagnosis
- Abstract
Survivors of childhood, adolescent, and young adult cancer, previously treated with anthracycline chemotherapy (including mitoxantrone) or radiotherapy in which the heart was exposed, are at increased risk of cardiomyopathy. Symptomatic cardiomyopathy is typically preceded by a series of gradually progressive, asymptomatic changes in structure and function of the heart that can be ameliorated with treatment, prompting specialist organisations to endorse guidelines on cardiac surveillance in at-risk survivors of cancer. In 2015, the International Late Effects of Childhood Cancer Guideline Harmonization Group compiled these guidelines into a uniform set of recommendations applicable to a broad spectrum of clinical environments with varying resource availabilities. Since then, additional studies have provided insight into dose thresholds associated with a risk of asymptomatic and symptomatic cardiomyopathy, have characterised risk over time, and have established the cost-effectiveness of different surveillance strategies. This systematic Review and guideline provides updated recommendations based on the evidence published up to September, 2020., Competing Interests: Declaration of interests AN reports research support from Amgen; a research contract with Bristol Myers Squibb; consulting fees from AstraZeneca, Boehringer Ingelheim, and Bantam Pharmaceuticals; and participation on a data safety monitoring board for Takeda Oncology. CP reports personal honoraria and expenses for presentation at education meetings from Amgen, Incyte, Ipsen, Novartis, and Servier. LSC reports grant funding from the University of Alabama for the Children's Oncology Group Guidelines, payment or honoraria for lectures or presentations from the American Society of Hematology and the University of Miami, and participation in the National Cancer Institute PDQ Pediatric Oncology Board. EJC is the Principal Investigator on a research grant to his institution from Abbott Laboratories. All other authors declare no competing interests., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
12. What is the diagnostic yield of bone marrow aspiration to exclude leukaemia prior to systemic treatment in juvenile idiopathic arthritis?
- Author
-
Fordham NJ, Bartram J, Ghorashian S, O'Connor D, Taylor A, Sibson K, Rao A, Pavasovic V, Cheng D, Ancliff P, Vora A, and Samarasinghe S
- Subjects
- Humans, Bone Marrow, Arthritis, Juvenile diagnosis, Arthritis, Juvenile drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma diagnosis
- Published
- 2022
- Full Text
- View/download PDF
13. Blinatumomab for paediatric mixed phenotype acute leukaemia.
- Author
-
Bartram J, Balasch-Carulla M, Bhojaraja S, Adams S, Cheng D, Inglott S, Kulkarni N, Mahendrayogam A, O'Connor O, Pavasovic V, and Vora A
- Subjects
- Aged, Antibodies, Bispecific administration & dosage, Antibodies, Bispecific pharmacology, Antigens, CD19 drug effects, Antigens, CD19 genetics, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Combined Modality Therapy methods, Female, Hematopoietic Stem Cell Transplantation methods, Histone-Lysine N-Methyltransferase drug effects, Histone-Lysine N-Methyltransferase genetics, Humans, Infant, Leukemia, Biphenotypic, Acute genetics, Leukemia, Biphenotypic, Acute pathology, Male, Myeloid-Lymphoid Leukemia Protein drug effects, Myeloid-Lymphoid Leukemia Protein genetics, Neoplasm, Residual genetics, Neoplasm, Residual pathology, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma genetics, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma pathology, Progression-Free Survival, Remission Induction, Treatment Outcome, Antibodies, Bispecific therapeutic use, Leukemia, Biphenotypic, Acute drug therapy, Neoplasm, Residual drug therapy, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma drug therapy
- Published
- 2021
- Full Text
- View/download PDF
14. Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.
- Author
-
van Atteveld JE, Mulder RL, van den Heuvel-Eibrink MM, Hudson MM, Kremer LCM, Skinner R, Wallace WH, Constine LS, Higham CE, Kaste SC, Niinimäki R, Mostoufi-Moab S, Alos N, Fintini D, Templeton KJ, Ward LM, Frey E, Franceschi R, Pavasovic V, Karol SE, Amin NL, Vrooman LM, Harila-Saari A, Demoor-Goldschmidt C, Murray RD, Bardi E, Lequin MH, Faienza MF, Zaikova O, Berger C, Mora S, Ness KK, Neggers SJCMM, Pluijm SMF, Simmons JH, and Di Iorgi N
- Subjects
- Adolescent, Adult, Bone Diseases, Metabolic complications, Child, Humans, Risk Factors, Young Adult, Bone Density, Cancer Survivors statistics & numerical data, Epidemiological Monitoring
- Abstract
Childhood, adolescent, and young adult cancer survivors are at increased risk of reduced bone mineral density. Clinical practice surveillance guidelines are important for timely diagnosis and treatment of these survivors, which could improve bone mineral density parameters and prevent fragility fractures. Discordances across current late effects guidelines necessitated international harmonisation of recommendations for bone mineral density surveillance. The International Late Effects of Childhood Cancer Guideline Harmonization Group therefore established a panel of 36 experts from ten countries, representing a range of relevant medical specialties. The evidence of risk factors for very low and low bone mineral density and fractures, surveillance modality, timing of bone mineral density surveillance, and treatment of very low and low bone mineral density were evaluated and critically appraised, and harmonised recommendations for childhood, adolescent, and young adult cancer survivors were formulated. We graded the recommendations based on the quality of evidence and balance between potential benefits and harms. Bone mineral density surveillance is recommended for survivors treated with cranial or craniospinal radiotherapy and is reasonable for survivors treated with total body irradiation. Due to insufficient evidence, no recommendation can be formulated for or against bone mineral density surveillance for survivors treated with corticosteroids. This surveillance decision should be made by the survivor and health-care provider together, after careful consideration of the potential harms and benefits and additional risk factors. We recommend to carry out bone mineral density surveillance using dual-energy x-ray absorptiometry at entry into long-term follow-up, and if normal (Z-score > -1), repeat when the survivor is aged 25 years. Between these measurements and thereafter, surveillance should be done as clinically indicated. These recommendations facilitate evidence-based care for childhood, adolescent, and young adult cancer survivors internationally., Competing Interests: Declaration of interests LMW received grants and personal fees from Novartis and Amgen (with funds to the Children's Hospital of Eastern Ontario Research Institute). KKN received grants from the National Institutes of Health and the American Lebanese Syrian Associated Charities. All other authors declare no competing interests., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
15. Clinical Utility of Radiologic Disease Reassessment in the Management of Pediatric B-Cell Non-Hodgkin Lymphoma.
- Author
-
Green K, Pavasovic V, Ghorashian S, Ancliff P, Bartram J, Rao A, Samarasinghe S, Vora A, Cheng D, and O'Connor D
- Subjects
- Adolescent, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Child, Child, Preschool, Disease Management, Female, Humans, Infant, Lymphoma, B-Cell drug therapy, Lymphoma, B-Cell pathology, Magnetic Resonance Imaging, Male, Neoplasm, Residual diagnostic imaging, Neoplasm, Residual drug therapy, Neoplasm, Residual pathology, Prognosis, Retrospective Studies, Tomography, X-Ray Computed, Ultrasonography, Lymphoma, B-Cell diagnostic imaging
- Abstract
Although outcomes for children with B-cell non-Hodgkin lymphoma are excellent, between 20% and 40% demonstrate residual radiologic abnormalities at disease assessment during consolidation therapy, the significance of which remains uncertain. The authors report the outcomes for all children treated for B-cell non-Hodgkin lymphoma at our center over an 11-year period. Twenty-four of 64 (38%) children had residual radiologic abnormalities at disease remission assessment. Seven (29%) underwent histologic biopsies that were normal. No children with residual radiologic abnormalities experienced disease relapse or death, suggesting that imaging at this time point creates clinical uncertainty without indicating residual disease or predicting relapse., Competing Interests: The authors declare no conflict of interest., (Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
16. Congenital acute myeloid leukemia: challenges and lessons. A 15-year experience from the UK.
- Author
-
Green K, Tandon S, Ahmed M, Toscano W, O'Connor D, Ancliff P, Vora A, Bartram J, Samarasinghe S, Ghorashian S, Pavasovic V, and Rao A
- Subjects
- Adolescent, Antineoplastic Combined Chemotherapy Protocols adverse effects, Cardiotoxicity, Child, Humans, Remission Induction, Retrospective Studies, United Kingdom epidemiology, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute epidemiology, Leukemia, Myeloid, Acute therapy
- Abstract
Congenital Acute Myeloid leukemia (CAML) is a rare leukemia diagnosed within the first 28 days of life. Dismal survival rates of approximately 25% at two years from diagnosis have not improved despite multiple treatment protocols, and there lacks international consensus for optimal management of these vulnerable patients. We report a retrospective analysis of our fifteen-year experience from a large UK tertiary pediatric center, focusing on treatment modalities and outcomes, including late therapeutic toxicities. To our knowledge, this is the first UK series of congenital leukemia patients reported. Twelve patients with a median age of 16.4 days (1-60) were diagnosed with CAML in fifteen years. All patients presented unwell; 92% demonstrating skin involvement. 10 (83%) received chemotherapy; with 1 death at presentation and 1 spontaneous remission. 5 (42%) received subsequent stem cell transplant. Only 4 (33%) remain alive, with 5 (42%) dying in disease remission with treatment-related mortality. Documented cardiotoxicity was observed in 3 (25%) patients, with a further 2 (17%) suspected but not receiving postmortem. Treatment of congenital AML raises challenging diagnostic, therapeutic and ethical questions and requires multi-center, international collaboration to see improvements.
- Published
- 2021
- Full Text
- View/download PDF
17. Guidance regarding COVID-19 for survivors of childhood, adolescent, and young adult cancer: A statement from the International Late Effects of Childhood Cancer Guideline Harmonization Group.
- Author
-
Verbruggen LC, Wang Y, Armenian SH, Ehrhardt MJ, van der Pal HJH, van Dalen EC, van As JW, Bardi E, Baust K, Berger C, Castagnola E, Devine KA, Gebauer J, Marchak JG, Glaser AW, Groll AH, Haeusler GM, den Hartogh J, Haupt R, Hjorth L, Kato M, Kepák T, Koopman MMWR, Langer T, Maeda M, Michel G, Muraca M, Nathan PC, van den Oever SR, Pavasovic V, Sato S, Schulte F, Sung L, Tissing W, Uyttebroeck A, Mulder RL, Kuehni C, Skinner R, Hudson MM, and Kremer LCM
- Subjects
- Adolescent, Adult, COVID-19, Child, Child, Preschool, Coronavirus Infections epidemiology, Coronavirus Infections transmission, Female, Humans, Male, Neoplasms epidemiology, Pneumonia, Viral epidemiology, Pneumonia, Viral transmission, Practice Guidelines as Topic, SARS-CoV-2, Young Adult, Betacoronavirus, Cancer Survivors, Coronavirus Infections prevention & control, Coronavirus Infections therapy, Neoplasms therapy, Pandemics prevention & control, Pneumonia, Viral prevention & control, Pneumonia, Viral therapy
- Abstract
Childhood, adolescent, and young adult (CAYA) cancer survivors may be at risk for a severe course of COVID-19. Little is known about the clinical course of COVID-19 in CAYA cancer survivors, or if additional preventive measures are warranted. We established a working group within the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) to summarize existing evidence and worldwide recommendations regarding evidence about factors/conditions associated with risk for a severe course of COVID-19 in CAYA cancer survivors, and to develop a consensus statement to provide guidance for healthcare practitioners and CAYA cancer survivors regarding COVID-19., (© 2020 Wiley Periodicals LLC.)
- Published
- 2020
- Full Text
- View/download PDF
18. CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy.
- Author
-
Leong S, Inglott S, Papaleonidopoulou F, Orfinada K, Ancliff P, Bartram J, Carpenter B, Fielding AK, Ghorashian S, Grandage V, Gupta R, Hough R, Khwaja A, Pavasovic V, Rao A, Samarasinghe S, Vora A, Mansour MR, and O'Connor D
- Subjects
- Adult, Child, Humans, Immunotherapy, Neoplasm Recurrence, Local, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
- Published
- 2020
- Full Text
- View/download PDF
19. Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection.
- Author
-
Orf K, Rogosic S, Dexter D, Ancliff P, Badle S, Brierley J, Cheng D, Dalton C, Dixon G, Du Pré P, Grandjean L, Ghorashian S, Mittal P, O'Connor D, Pavasovic V, Rao A, Samarasinghe S, Vora A, Bamford A, and Bartram J
- Subjects
- Adenosine Monophosphate administration & dosage, Alanine administration & dosage, COVID-19, Child, Preschool, Humans, Male, SARS-CoV-2, Adenosine Monophosphate analogs & derivatives, Alanine analogs & derivatives, Betacoronavirus metabolism, Coronavirus Infections diagnosis, Coronavirus Infections drug therapy, Coronavirus Infections etiology, Induction Chemotherapy, Pandemics, Pneumonia, Viral diagnosis, Pneumonia, Viral drug therapy, Pneumonia, Viral etiology, Precursor Cell Lymphoblastic Leukemia-Lymphoma complications, Precursor Cell Lymphoblastic Leukemia-Lymphoma diagnosis, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma virology
- Published
- 2020
- Full Text
- View/download PDF
20. Blinatumomab for infant acute lymphoblastic leukemia.
- Author
-
Clesham K, Rao V, Bartram J, Ancliff P, Ghorashian S, O'Connor D, Pavasovic V, Rao A, Samarasinghe S, Cummins M, Malone A, Patrick K, Bonney D, James B, Gibson B, and Vora A
- Subjects
- Child, Preschool, Female, Follow-Up Studies, Humans, Infant, Infant, Newborn, Male, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology, Prognosis, Retrospective Studies, Survival Rate, Antibodies, Bispecific therapeutic use, Antineoplastic Agents therapeutic use, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy
- Published
- 2020
- Full Text
- View/download PDF
21. The incidence of invasive fungal infections in children, adolescents and young adults with acute lymphoblastic leukaemia/lymphoma treated with the UKALL2011 protocol: a multicentre retrospective study.
- Author
-
O'Reilly MA, Govender D, Kirkwood AA, Vora A, Samarasinghe S, Khwaja A, Grandage V, Rao A, Ancliff P, Pavasovic V, Cheng D, Carpenter B, Daw S, Hough R, and O'Connor D
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Female, Humans, Incidence, Infant, London epidemiology, Male, Retrospective Studies, Risk Factors, Young Adult, Antifungal Agents administration & dosage, Antifungal Agents pharmacokinetics, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Invasive Fungal Infections blood, Invasive Fungal Infections chemically induced, Invasive Fungal Infections drug therapy, Invasive Fungal Infections epidemiology, Precursor Cell Lymphoblastic Leukemia-Lymphoma blood, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma epidemiology
- Published
- 2019
- Full Text
- View/download PDF
22. Orbital mass secondary to infantile acute lymphoblastic leukaemia.
- Author
-
Hossain IT, Moosajee M, Abou-Rayyah Y, and Pavasovic V
- Subjects
- Antineoplastic Agents therapeutic use, Diagnosis, Differential, Female, Humans, Infant, Prednisolone therapeutic use, Prognosis, Treatment Outcome, Orbital Neoplasms diagnostic imaging, Orbital Neoplasms drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma diagnostic imaging, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy
- Abstract
An 8-month-old Asian infant girl was referred with a 1-week history of left periorbital swelling on a background of a narrowed left palpebral aperture over the preceding 8 weeks. There was no history of chronic illness, fever or other systemic features. Examination revealed a tender and fluctuant medial canthal swelling with associated periorbital haematoma. There were no other ophthalmic findings and neurological examination was normal. A MRI scan of the brain and orbit demonstrated abnormal soft tissue with features of an aggressive tumour in the left orbital region with no globe invasion. Peripheral blood smear revealed blast cells, confirmed by bone marrow aspirate. A diagnosis of infant acute lymphoblastic leukaemia was made. The patient was started on risk-stratified chemotherapy according to the Interfant-06 Protocol The periorbital swelling resolved by day eight following a course of prednisolone, the patient continues on chemotherapy and is currently in molecular remission., (2016 BMJ Publishing Group Ltd.)
- Published
- 2016
- Full Text
- View/download PDF
23. Biomarkers to detect Wilms tumors in pediatric patients: where are we now?
- Author
-
Charlton J, Pavasovic V, and Pritchard-Jones K
- Subjects
- Adolescent, Child, Child, Preschool, Epigenesis, Genetic genetics, Humans, Prognosis, Wilms Tumor pathology, Biomarkers, Tumor genetics, MicroRNAs genetics, Neoplasm Proteins genetics, Wilms Tumor genetics
- Abstract
Wilms tumor (WT) is the most common pediatric renal tumor. Survival rates are high, whether treated according to the European protocols (SIOP-RTSG) that use prenephrectomy chemotherapy or the Children's Oncology Group (COG) protocols, with immediate nephrectomy. However, the more intensive treatment given to higher risk subgroups may result in late effects. Current risk stratification does not identify all tumors that relapse and loss of heterozygosity of 16q and 1p are the only molecular biomarkers used in risk stratification. In this review we describe recent new genetic and epigenetic findings in WT and discuss their potential use as biomarkers. We discuss approaches to ensure representative sampling of WTs including the potential for 'liquid biopsy' to circumvent intratumoral heterogeneity.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.